{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Head+and+Neck+Carcinoma",
    "query": {
      "condition": "Advanced Head and Neck Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 870,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Head+and+Neck+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T12:00:42.463Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04731467",
      "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Papillary Thyroid Cancer",
        "Melanoma",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "CM-24 and Nivolumab - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion",
          "type": "DRUG"
        },
        {
          "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Famewave Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2021-03-19",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04731467"
    },
    {
      "nct_id": "NCT05743270",
      "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck",
        "Locally Advanced Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "RP3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CCRT(concurrent chemoradiation therapy)",
          "type": "OTHER"
        },
        {
          "name": "carboplatin and paclitaxel",
          "type": "OTHER"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-01-30",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743270"
    },
    {
      "nct_id": "NCT00701857",
      "title": "Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-02",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-04-20",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00701857"
    },
    {
      "nct_id": "NCT04881045",
      "title": "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07257876",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2021-08-18",
      "completion_date": "2023-10-24",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04881045"
    },
    {
      "nct_id": "NCT02454179",
      "title": "Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2015-05",
      "completion_date": "2018-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454179"
    },
    {
      "nct_id": "NCT04354246",
      "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Ovarian Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "Plasma Cell Neoplasm",
        "Multiple Myeloma",
        "HNSCC",
        "Microsatellite Stable Colorectal Carcinoma",
        "MSS-CRC"
      ],
      "interventions": [
        {
          "name": "Dose escalation: COM902 monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort expansion: COM902 (RDFE) monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: COM902 in combination with COM701 (both at the RDFE).",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Compugen Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2020-03-31",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 9,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04354246"
    },
    {
      "nct_id": "NCT03854227",
      "title": "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PF-06939999 dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-06939999 monotherapy",
          "type": "DRUG"
        },
        {
          "name": "PF-06939999 in combination with docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2019-03-14",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 22,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03854227"
    },
    {
      "nct_id": "NCT01495663",
      "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "I-131-CLR1404",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellectar Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495663"
    },
    {
      "nct_id": "NCT05678348",
      "title": "Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Cancer of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Pyrimethamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2023-08-03",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05678348"
    },
    {
      "nct_id": "NCT03058289",
      "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma",
        "Lymphoma",
        "Pancreatic Cancer",
        "Liver Cancer",
        "Colon Cancer",
        "Lung Cancer",
        "Bile Duct Cancer",
        "Chordoma of Sacrum",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "INT230-6",
          "type": "DRUG"
        },
        {
          "name": "anti-PD-1 antibody",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-CTLA-4 antibody",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Intensity Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2017-02-09",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-06-25T12:00:42.463Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03058289"
    }
  ]
}